Aadi Bioscience (AADI)
(Delayed Data from NSDQ)
$2.11 USD
-0.04 (-1.86%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $2.10 -0.01 (-0.47%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.11 USD
-0.04 (-1.86%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $2.10 -0.01 (-0.47%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
Zacks News
Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aadi Bioscience (AADI) delivered earnings and revenue surprises of 23.94% and 2.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 600% and 2.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Aadi Bioscience, Inc. (AADI) have performed compared to their sector so far this year.
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 10.45% and 2.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 10.81% and 91.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of 7.14% and 66.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 0% and 20.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in Aadi Bioscience, Inc. (AADI)? Wall Street Analysts Think 509.98%
by Zacks Equity Research
The mean of analysts' price targets for Aadi Bioscience, Inc. (AADI) points to a 510% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of -4.69% and 0.31%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 1.35% and 69.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Aadi Bioscience, Inc. (AADI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 1.72% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 25.64% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 5.56% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 20% and 14.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of 9.09% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 6.38% and 2.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Brookdale Senior Living (BKD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Brookdale (BKD) delivered earnings and revenue surprises of 69.77% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Aadi Bioscience, Inc. (AADI) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Aadi Bioscience, Inc. (AADI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 9.33% and 18.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of -132.20% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Preferred Apartment Communities, GCM Grosvenor, Aadi Bioscience and Vivint Smart Home
by Zacks Equity Research
Zacks.com featured highlights include: Preferred Apartment Communities, GCM Grosvenor, Aadi Bioscience and Vivint Smart Home
4 Stocks to Reap Solid Returns as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like Preferred Apartment (APTS), GCM (GCMG), Aadi (AADI) & Vivint (VVNT).